Cleveland Clinic Cancer Center (Taussig) Outcomes
Multiple Myeloma
Multiple Myeloma
Outcomes for patients with multiple myeloma treated at Taussig Cancer Institute compare favorably with other reported outcomes. Life expectancy has not significantly changed since 2007, but there are too few patients in long-term follow-up for the cohort of patients who may derive benefit from recently approved drugs. Overall favorable data may reflect care by a specialized healthcare team, common use of maintenance therapy in myeloma, and access to novel therapies, including within the context of clinical trials. Cleveland Clinic is also one of two sites in the United States selected to trial AMG 424, an anti-CD38/CD3 bispecific T cell-recruiting antibody for relapsed and refractory multiple myeloma.
Five-Year Overall Survival of Patients With Multiple Myeloma After Start of Treatment (N = 1315)
2011-2021
| Number at Risk | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 |
|---|---|---|---|---|---|
| 2011-2016 (N = 705) | 614 | 523 | 455 | 389 | 266 |
| 2017-2021 (N = 610) | 399 | 238 | 102 | 26 | 2 |
ᵃNational comparison represents relative survival after diagnosis from Cancer Stat Facts: An interactive tool for access to Surveillance, Epidemiology, and End Results (SEER) cancer statistics. Surveillance Research Program, National Cancer Institute. https://seer.cancer.gov/statfacts/html/mulmy.html. Accessed June 27, 2022.
Based on SEER 17 data, patients with multiple myeloma diagnosed between 2012 and 2018 had a 5-year relative survival rate of 57.9% from time of diagnosis, meaning death from other causes is not counted in this number, whereas it is counted in our analysis.
Five-Year Overall Survival of Patients With Multiple Myeloma by Age at Start of Treatment (N = 1315)
2011-2021
| Number at Risk | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 |
|---|---|---|---|---|---|
| 2011-2016, < 75 (N = 574) | 515 | 440 | 388 | 340 | 236 |
| 2011-2016, ≥ 75 (N = 131) | 99 | 83 | 67 | 49 | 30 |
| 2017-2021, < 75 (N = 492) | 334 | 200 | 90 | 22 | 2 |
| 2017-2021, ≥ 75 (N = 118) | 65 | 38 | 12 | 4 | 0 |
The improvement of outcomes for myeloma in recent years is still limited to patients < 75 years of age at the start of therapy who had 5-year survival estimates of around 60% compared to around 30% for patients age 75 or older at the start of myeloma therapy. Although these data are not adjusted for age-related life expectancy, lack of improvement in relative survival has been reported for this age group.¹
